Evidence map›Paper›PMID 35077243›Full record

ArticleJournal of cardiovascular pharmacology and therapeutics

The Association of Alanine Aminotransferase Levels With Myocardial Perfusion Imaging and Cardiovascular Morbidity.

David Yardeni, Ronen Toledano, Victor Novack, Aryeh Shalev, Arik Wolak, Yaron Rotman, Ohad Etzion

Open access · goldAbstract read
In one paragraph

Article in Journal of cardiovascular pharmacology and therapeutics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

David YardeniDepartment of Gastroenterology and Liver Diseases, 26746Soroka University Medical Center, Beer-Sheva, Israel.ORCID 0000-0002-4078-7173
Ronen ToledanoClinical Research Center, 26746Soroka University Medical Center, Beer-Sheva, Israel.
Victor NovackClinical Research Center, 26746Soroka University Medical Center, Beer-Sheva, Israel.
Aryeh ShalevCardiology Department, 26746Soroka University Medical Center, Beer-Sheva, Israel.
Arik WolakCardiology Department, 26743Shaare Zedek Medical Center, Jerusalem, Israel.
Yaron RotmanLiver and Energy Metabolism Section, Liver Diseases Branch, 2511National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Ohad EtzionDepartment of Gastroenterology and Liver Diseases, 26746Soroka University Medical Center, Beer-Sheva, Israel.
Soroka Medical Center · ILNational Institutes of Health · USShaare Zedek Medical Center · IL

Funding

Nonalcoholic Steatohepatitis: Natural History, Pathogenesis and TherapyZIADK075013 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI ROTMAN, YARON · 2009 to 2025
$19.1M
Intramural NIH HHS Z99 DK999999Intramural NIH HHS ZIA DK075013
6 · The paper itself

Abstract

introductionStudies suggest that non-alcoholic fatty liver disease (NAFLD) is associated with an independent risk of cardiovascular disease (CVD). We utilized a large cohort of patients undergoing myocardial perfusion imaging (MPI) with single photon emission computed tomography (SPECT) to determine the association between alanine aminotransferase (ALT) as a surrogate marker for presumed NAFLD, and the presence of myocardial ischemia and mortality.

methodsWe retrospectively assessed SPECT-MPI results and medical records of individuals evaluated between 1997 and 2008. We excluded patients with known non-NAFLD liver diseases, ALT values <17 or >340 U/L and absent liver tests. Elevated ALT cases were classified as presumed NAFLD. The primary endpoint was abnormal SPECT-MPI. Secondary endpoints included cardiac death, acute myocardial infarction and all-cause mortality.

resultsOf 26,034 patients who underwent SPECT-MPI, 11,324 met inclusion criteria. 1635 (14.4%) patients had elevated ALT. SPECT-MPI results did not differ significantly between subjects with elevated ALT and controls. Elevated ALT was associated with increased risk for the composite endpoint of cardiac death or acute myocardial infarction at 5-year follow-up (hazard ratio [HR] 1.3, 95% confidence interval [CI] 1.01-1.67) and in all-cause mortality (HR 1.27, CI 1.02-1.58) but only in patients with normal SPECT-MPI.

conclusionsThe long-term mortality of patients with abnormal SPECT-MPI is not modulated by ALT, likely reflecting an already high risk and established CVD. However, patients with normal SPECT-MPI are at increased risk for a future cardiac event if they have an elevated ALT level, suggesting an important role for NAFLD in earlier stages of CVD.

Indexed as

AgedAlanine TransaminaseCardiovascular DiseasesCause of DeathCohort StudiesFemaleHumansIsraelMaleMiddle AgedMyocardial IschemiaMyocardial Perfusion ImagingNon-alcoholic Fatty Liver DiseaseTomography, Emission-Computed, Single-PhotonAlanine Transaminasecardiovascular diseasefatty liverheart disease risk factorsmetabolic syndromeperfusion imaging

Identifiers

PMID35077243
PMCPMC8840806
OpenAlexW4207057742

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.